

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM852031

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
American Gene Technologies International Inc.		10/31/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Wilmington Trust, National Association, as Collateral Agent		
Street Address:	50 South Sixth Street, Suite 1290		
City:	Minneapolis		
State/Country:	MINNESOTA		
Postal Code:	55402		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	97804562	ADDIMMUNE	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2023704750		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	Rodney Boulware		
Address Line 1:	1025 Connecticut Ave NW, Suite 712		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	Washington, D.C. 20036		
ATTORNEY DOCKET NUMBER:	2175411 TM		
NAME OF SUBMITTER:	ANDREW NASH		
SIGNATURE:	/ANDREW NASH/		
DATE SIGNED:	11/08/2023		
Total Attachments: 41			
source=AGT - Intellectual Property Security Agreement -- Dated as of 10.31.2023 (Executed)#page1.tif			
source=AGT - Intellectual Property Security Agreement -- Dated as of 10.31.2023 (Executed)#page2.tif			
source=AGT - Intellectual Property Security Agreement -- Dated as of 10.31.2023 (Executed)#page3.tif			

OP \$40.00 97804562

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (“**Agreement**”) is executed on October 31, 2023 by American Gene Technologies International Inc., a Delaware corporation (together with its successors and assigns, “**Grantor**”), in favor of Wilmington Trust, National Association, a national banking association, as collateral agent (in such capacity, together with its successors in such capacity, the “**Collateral Agent**”) on behalf of the Investors listed on the signature pages hereof.

RECITALS

A. Grantor issued senior secured convertible promissory notes as amended, modified or otherwise supplemented from time to time, (each a “**Note**” and collectively, the “**Notes**”) to the Investors pursuant to that certain Senior Secured Convertible Promissory Note Purchase Agreement, dated as of the date hereof (as amended and restated from time to time) (the “**Purchase Agreement**”).

B. Certain of the Investors have agreed to extend credit to Grantor in the amounts and manner set forth in the Purchase Agreement. Capitalized terms used herein are used as defined in the Purchase Agreement. The Investors are willing to extend credit to Grantor pursuant to the Notes, but only upon the condition, among others, that Grantor shall grant to the Collateral Agent, on behalf of the Investors (i) a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) and (ii) a security interest in certain collateral of the Grantor, as set forth in that certain Security Agreement entered into on the date hereof (the “**Security Agreement**”), in each case, to secure the obligations of Grantor under the Notes.

C. Pursuant to the terms of the Security Agreement, Grantor has granted to the Collateral Agent on behalf of the Investors a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as defined in the Security Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Purchase Agreement and the Notes, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. **Grant of Security Interest.** To secure its obligations under the Purchase Agreement and the Notes, Grantor grants and pledges to the Collateral Agent, on behalf of the Investors, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”), provided that the term “Intellectual Property Collateral” shall not include intent-to-use trademark applications until such time as a statement of use is filed with the U.S. Patent and Trademark Office with respect to such intent-to-use trademark application;

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement, provided that the Collateral Agent agrees that the Grantor shall not record this agreement against any intent-to-use trademark applications.

3. Authorization. Grantor hereby authorizes the Collateral Agent (acting at the direction of Majority Note Holders) to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to add any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Transaction Documents. This Agreement has been entered into pursuant to and in conjunction with the Purchase Agreement and the Security Agreement. The provisions of the Security Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of the Investors with respect to the Intellectual Property Collateral are as provided by the Security Agreement, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., “pdf” or “tif” format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Additional Investors. Notwithstanding anything to the contrary contained herein, if the Grantor issues additional Notes after the date hereof, any Investor of such Notes may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed a “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as a “Investor” hereunder.

8. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).

9. Concerning the Collateral Agent. Wilmington Trust, National Association is entering this Agreement solely in its capacity as Collateral Agent under the Security Agreement and not in its individual capacity. In acting hereunder, the Collateral Agent shall be entitled to the rights, privileges, immunities and indemnities set forth in the Security Agreement, as if such rights, privileges, immunities and indemnities were set forth herein.

Signature Pages Follow.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

**AMERICAN GENE TECHNOLOGIES
INTERNATIONAL INC.**

By: 

Name: Jeffrey A. Galvin

Title: Chief Executive Officer

COLLATERAL AGENT:

**WILMINGTON TRUST, NATIONAL
ASSOCIATION**, as Collateral Agent

By: 


Name: Quinton M. DePompolo

Title: Assistant Vice President

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

Ned Caswell


DocuSigned by:
By: 
F928F46E7F7B47E...
Name: Ned Howard Caswell

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

GAINGELS 10X CAPITAL DIVERSITY
FUND I, LP

By: GAINGELS 10X CAPITAL DIVERSITY
FUND I, GP, General Partner

DocuSigned by:

6CE6543D6CA7433

By: Paul Grossinger

Title: Authorized Signatory

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: Eddie Gutierrez
008F0226CEBF3403...
Name: Eddie Gutierrez

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: William T Heberer
3086B132B462491...
Name: William T Heberer

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:

By: _____
08D38E002AC5405
Name: Stephanie Kleinjan

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


INVESTOR

DocuSigned by:
By: Steve Kleinjan
OF 8F-162B33D54F8...
Name: steve kleinjan

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

Samuel Lee

By:  _____
DocuSigned by:
8550C7AF09724B5...

Name: Samuel Lee

Title: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: Jeni Klugman
-----BEDA6A5046F54E3-----
Name: Jeni Klugman

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

Dale G. Leake and James W. Yard JTWROS

DocuSigned by:
By: Dale G. Leake
17557032C0F12402...
Name: Dale G. Leake

DocuSigned by:
By: James W. Yard
6C87CB1F104D483...
Name: James W. Yard


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: Brad Lerner
779914B36F42441
Name: Brad Lerner


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: 
BAAE0885E8C6458...
Name: Douglas Lister

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR


DocuSigned by:
By: 

Name: Marc Loev

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR


Don Morganstern

By:  _____
DocuSigned by:
2317FA8377F63430...

Name: Don Morganstern

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By:  _____
6CF48AFE3089425
Name: Matt Norden _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


INVESTOR


DocuSigned by:
By: Patrick Ostronic
A0E69E383E545A
Name: Patrick Ostronic

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

Paul D. Pachuta and Diana Pachuta

By: 
DocuSigned by:
EFC0FA1D8E3A344C...
Name: PAUL D PACHUTA

By: 
DocuSigned by:
EFDFA1DBE5A344C...
Name: Diana Pachuta


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: Drew Palin
054EEFF81B42446
Name: Drew Palin

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

By:  DocuSigned by:
E332548EC50D4C2...
Name: James Robinson
Title: member

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

ROC Venture Group – Gene, LLC

DocuSigned by:
By: Aaron Stafford
Name: Aaron Stafford
Title: Manager


Address for Notices:


4850 Tamiami Trail N. Suite 301
Naples, FL 3410

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

David and Gwen Silverstein

By: 
DocuSigned by:
00A65C065A9A35B...
Name: David Silverstein

By: 
DocuSigned by:
36A6251E2B9F4C2...
Name: Gwen Silverstein

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

Andrew Watson

DocuSigned by:
By: Andrew Watson
976A573E929443F...
Name: Andrew Watson

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

INVESTOR

DocuSigned by:
By: Lester Zuckerman
31186EC2F-38A859
Name: Lester Zuckerman

EXHIBIT A

Copyrights

None.

EXHIBIT B
Patents

Ref No.	Country	WGS No.	Title	Inventors	Applicant/ Assignee	Status	Serial/ Publication No.	Filing/ Publication/ Issue Date	Expiration Date
436313-000200	US		HIV Pre- Immunization and Immunotherapy	Pauza	AGT	Pending	15/736,284 2018-0177866	07/08/2016 06/28/2018	07/08/2036
436313-000205	Europe		HIV Pre- Immunization and Immunotherapy	Pauza	AGT	Pending	16822021.8 EP3319631	07/08/2016 05/16/2018	07/08/2036
436313-000210	Japan		HIV Pre- Immunization and Immunotherapy	Pauza	AGT	Issued	2017-567175 2018-524335 6890831	07/08/2016 08/30/2018 05/28/2021	07/08/2036
436313-000293	Japan		HIV Pre- Immunization and Immunotherapy	Pauza	AGT	Pending	2021-84813	07/08/2015	07/08/2035
436313-000400	US		HIV Vaccination and Immunotherapy	Pauza Lahusen Li	AGT	Issued	16/076,655 20190046633 10,888,613	08/08/2018 02/14/2019 01/12/2021	01/11/2037
436313-000417	US		Methods of Producing Cells Resistant to HIV Infection	Pauza Lahusen Li	AGT	Pending	17/089,468 2021-0121561	11/04/2020 04/29/2021	01/11/2037
436313-000405	Europe		HIV Vaccination and Immunotherapy	Pauza Lahusen Li	AGT	Pending	17750547.6 EP3413926	01/11/2017 12/19/2018	01/11/2037
436313-000410	Japan		HIV Vaccination and Immunotherapy	Pauza Lahusen Li	AGT	Issued	2018-541270 2019-509029 7153332	01/11/2017 04/04/2019 10/05/2022	01/11/2037
436313-000493	Japan		HIV Vaccination and Immunotherapy	Pauza Lahusen Li	AGT	Pending	2022-71538 2022-101658	01/11/2017 07/06/2022	01/11/2037
436313-001100	US		Hiv Pre-Immunization and Immunotherapy II	Pauza Li Lahusen Galvin	AGT	Issued	15/668,223 2018-0010147 10,036,038	08/03/2017 01/11/2018 07/31/2018	01/11/2037
436313-001101	Australia		Hiv Pre-Immunization and Immunotherapy II	Pauza Li Lahusen Galvin	AGT	Issued	2017292582 2017292582	01/11/2017 02/04/2021	01/11/2037

Ref No.	Country	WGS No.	Title	Inventors	Applicant/ Assignee	Status	Serial/ Publication No.	Filing/ Publication/ Issue Date	Expiration Date
436313-001199	Australia		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Pending	2021200210	01/11/2017	01/11/2037
436313-001103	Canada		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Pending	3,028,982	01/11/2017 01/11/2018	01/11/2037
436313-001105	Europe		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Pending	17824652.6 3481418	01/11/2017 05/15/2019	01/11/2037
436313-001109	Israel		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Issued	264064	01/11/2017 06/02/2021 06/30/2021	01/11/2037
436313-001198	Israel		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Issued	276038	01/11/2017 10/30/2021	01/11/2037
436313-001191	Israel		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Pending	284348	01/11/2017	01/11/2037
436313-001110	Japan		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Issued	2019-500475 2019-527055 6971492	01/11/2017 09/26/2019 11/05/2021	01/11/2037
436313-001117	US		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Issued	16/011,550 2018-0291399 10,233,464	06/18/2018 10/11/2018 03/19/2019	01/11/2037
436313-001136	US		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Issued	16/218,010 2019-0218573 10,494,647	12/12/2018 07/18/2019 12/03/2019	01/11/2037
436313-001137	US		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvin	AGT	Issued	16/593,882 2020-0109417 11,090,379	10/04/2019 04/09/2020 08/17/2021	01/11/2037

Ref No.	Country	WGS No.	Title	Inventors	Applicant/ Assignee	Status	Serial/ Publication No.	Filing/ Publication/ Issue Date	Expiration Date
436313-001138	US		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvyn	AGT	Issued	17/175,278 2021-0330783 11,612,649	02/12/2021 10/28/2021 03/28/2023	07/05/2037
436313-001139	US		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvyn	AGT	Pending	18/108,148 2023-0241200	02/10/2023 08/03/2023	01/11/2037
436313-001190	Japan		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Galvyn	AGT	Pending	2021-174409 2022-28677	01/11/2017 02/16/2022	01/11/2037
436313-001192	Japan		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Pending	2022-133225 2022-166288	07/07/2017 11/01/2022	07/07/2037
436313-001194	US		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Pending	16/312,056 2019-0201523	12/20/2018 07/04/2019	01/11/2037
436313-001195	Europe		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Pending	17825011,4 3481435	07/07/2017 05/15/2019	07/07/2037
436313-001196	Japan		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Issued	2019-500423 2019-525914 7162895	07/07/2017 09/12/2019 10/21/2022	01/11/2037
436313-001197	Israel		Hiv Pre-Immunization and Immunotherapy II	Paauza Li Lahusen Mansfield	AGT	Pending	300730	01/11/2017	01/11/2037
436313-001500	US		Hiv Treatment with No Pre-Immunization	Paauza Li Lahusen	AGT	Pending	16/476,529 2020-0384021	07/08/2019 12/10/2020	01/09/2038
436313-001501	Australia		Hiv Treatment with No Pre-Immunization	Li Paauza Lahusen	AGT	Pending	2018205388	01/09/2018	01/09/2038

Ref No.	Country	WGS No.	Title	Inventors	Applicant/ Assignee	Status	Serial/ Publication No.	Filing/ Publication/ Issue Date	Expiration Date
436313-001503	Canada		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	3,048,643	01/09/2018	01/09/2038
436313-001505	Europe		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	18736295.9 3565564	01/09/2018 11/13/2019	01/09/2038
436313-001508	Hong Kong		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	19133110.7 40009664	01/09/2018 06/26/2020	01/09/2038
436313-001509	Israel		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	267794	01/09/2018	01/09/2038
436313-001510	Japan		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Issued	2019-536901 2020-515234 7260170	01/09/2018 05/28/2020 04/10/2023	01/09/2038
436313-001511	Korea		Hypnotherapy with no Pre-Immunization Step	Li Pauza Lahusen	AGT	Pending	10-2019-7023287 10-2019-0104586	01/09/2018 09/10/2019	01/09/2038
436313-001528	Brazil		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	112019014082.4 2565	01/09/2018 03/03/2020	01/09/2038
436313-001534	China		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	201880016715.2 110462029	01/09/2018 11/15/2019	01/09/2038
436313-001556	India		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	201947031955	01/09/2018 08/23/2019	01/09/2038
436313-001590	Japan		Hiv Treatment with No Pre-Immunization	Li Pauza Lahusen	AGT	Pending	2022-189475 2023-15407	01/09/2018 01/31/2023	01/09/2038
436313-002700	US		Methods Of Manufacturing Genetically-Modified Lymphocytes	Li Pauza	AGT	Pending	17/042,043 2021-0015868	09/25/2020 01/21/2021	03/27/2039
436313-002705	Europe		Methods Of Manufacturing Genetically-Modified Lymphocytes	Li Pauza	AGT	Pending	19777212.2 3773622	03/27/2019 02/17/2021	03/27/2039

Ref No.	Country	WGS No.	Title	Inventors	Applicant/ Assignee	Status	Serial/ Publication No.	Filing/ Publication/ Issue Date	Expiration Date
436313-002710	Japan		Methods Of Manufacturing Genetically-Modified Lymphocytes	Li Pauza	AGT	Pending	2020-551499	03/27/2019	03/27/2039
436313-002711	Korea		Methods of Manufacturing Genetically-Modified Lymphocytes	Li Pauza	AGT	Pending	10-2020-7030636 10-2020-0135852	03/27/2019 12/03/2020	03/27/2039
436313-003700	US		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	17/908,509	08/31/2022	03/03/2041
436313-003701	Australia		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	2021232603	03/03/2021	03/03/2041
436313-003703	Canada		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	3,170,630	03/03/2021	03/03/2041
436313-003705	Europe		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	21764102.6 EP4114439	03/03/2021 01/11/2023	03/03/2041
436313-003708	Hong Kong		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	62023067179.9 HK40078678A	03/03/2021 03/31/2023	03/03/2041
436313-003709	Israel		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	296096	03/03/2021	03/03/2041

Ref No.	Country	WGS No.	Title	Inventors	Applicant/ Assignee	Status	Serial/ Publication No.	Filing/ Publication/ Issue Date	Expiration Date
436313-003710	Japan		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	2022-552807 2023-516685	03/03/2021 04/20/2023	03/03/2041
436313-003711	Korea		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	10-2022-7033216	03/03/2021	03/03/2041
436313-003728	Brazil		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	112022017678 3	03/03/2021 11/08/2022	03/03/2041
436313-003734	China		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	202180032693.0 CN115551532A	03/03/2021 12/30/2022	03/03/2041
436313-003756	India		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	2022247055000	03/03/2021 10/07/2022	03/03/2041
436313-003790	UAE		On Demand Expression of Exogenous Factors in Lymphocytes to Treat Hiv	Li Lahusen Pauza	AGT	Pending	P6001731/2022	03/03/2021	03/03/2041

EXHIBIT C

Trademarks

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004700	United States	ADDIMMUNE	Company	97/804,562	Pending	02/23/23	Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
436313-004701	Australia	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Filed as intent-to-use (IB) basis Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004703	Canada	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
436313-004705	Europe	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004708	Hong Kong	ADDIMMUNE	Company	306232978	Pending	05/02/23	Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
436313-004710	Japan	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
436313-004711	Korea	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV.

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004713	Mexico	ADDIMMUNE	Company	A0134961	Pending	05/01/23	Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research
436313-004721	United Kingdom	ADDIMMUNE	Company	A0134961	Pending	05/01/23	Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals,

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004728	Brazil	ADDIMMUNE	Company	A0134961	Pending	05/01/23	<p>medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders</p> <p>IC 042. US 100 101. G & S; pharmaceutical research and development services; biological research; medical research</p> <p>Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV.</p> <p>Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders</p>
436313-004734	China	ADDIMMUNE	Company	A0134961	Pending	05/01/23	<p>IC 042. US 100 101. G & S; pharmaceutical research and development services; biological research; medical research</p> <p>Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV.</p> <p>Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders</p>

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004756	India	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
436313-004777	Russian Federation	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research

Ref. No.	Country	Mark	Record Owner	Application Number or Registration	Status	Date of Filing or Issuance	Goods/Services
436313-004780	Singapore	ADDIMMUNE	Company	A0134961	Pending	05/01/23	Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
436313-004790	Indonesia	ADDIMMUNE	Company	A0134961	Pending	05/01/23	IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research Class 5: pharmaceuticals, medicinal and biological preparations for the treatment of HIV; a house mark for pharmaceuticals and pharmaceutical preparations for the treatment of HIV. Class 41: providing online newsletters in the fields of pharmaceuticals, medicines, treatments of diseases and medical disorders, HIV, and health; providing online non-downloadable videos in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; online journals, namely, blogs featuring pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders; educational services, namely, conducting programs in the fields of pharmaceuticals, medicines, treatments of diseases, HIV, and medical disorders
							IC 042. US 100 101. G & S: pharmaceutical research and development services; biological research; medical research

EXHIBIT D

Mask Works

None.